SyntekaBio

SyntekaBio Debt / Assets

Debt-to-Assets Ratio of SyntekaBio (226330.KQ) as of Nov 20, 2026.

Debt / Assets

0.00

YoY

-96.45%

Last updated:

Debt-to-Assets Ratio of SyntekaBio is 2022 0.00 . Debt-to-Assets Ratio of SyntekaBio was 2021 0.13 . It decreases by -96.45% lower compared to the previous year.

The SyntekaBio Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2017
0.14 KRW
Jan 1, 2018
0.00 KRW
Jan 1, 2019
0.00 KRW
Jan 1, 2020
0.01 KRW
Jan 1, 2021
0.13 KRW
Jan 1, 2022
0.00 KRW
The SyntekaBio Debt / Assets history
YEARDebt / AssetsYoY
0.00-96.45%
0.13+931.76%
0.01+293.61%
0.00—
0.00-100.00%
0.14—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's SyntekaBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SyntekaBio

All Key Metrics — SyntekaBio